Νέα 2020

 24 προϊόντα προηγμένης βιοτεχνολογίας χρησιμοποιούνται σήμερα σε κλινικές μελέτες  για τη θεραπεία των επιπλοκών του κορωνοϊού.

10 εξ αυτών προέρχονται από το ομφαλοπλακουντιακό αίμα, τον πλακούντα και τον ιστό του ομφαλίου λώρου  

·     Ankylosaurus; M1 macrophages target

·     Aerosol inhalation of vMIP: viral macrophage inflammatory protein

·     Anti-2019-nCoV inactivated convalescent plasma

·     Anti-SARS-CoV-2 inactivated convalescent plasma

·     Biological preparation of human placenta

·     Convalescent plasma treatment

·     Cord blood mesenchymal stem cells

·     Human menstrual blood-derived stem cells

·     Immunoglobulin from cured patients

·     Inactivated Mycobacterium vaccine

·     Infusion of convalescent plasma

·     Mesenchymal stem cells

·     Mesenchymal stem cells exosomes atomization

·     mRNA-1273

·     NK cells

·     Plasma treatment

·     Recombinant cytokine gene-derived protein injection

·     Regulating intestinal flora

·     Therapeutic antibody from recovered novel coronavirus pneumonia patients

·     Umbilical cord blood mononuclear cells

·     Umbilical cord mesenchymal stem cells (hucMSCs)

·     Umbilical cord Wharton’s Jelly derived mesenchymal stem cells

·     Umbilical Cord(UC)-derived mesenchymal stem cells

·     Washed microbiota transplantation

Carl Heneghan is the Editor in Chief BMJ EBM and Professor of EBM, Centre for Evidence-Based Medicine in the Nuffield Department of Primary Care Health Sciences, University of Oxford

Oxford     https://www.cebm.net/covid-19/registered-trials-and-analysis/